Pancreatic Cancer Research

ResearcherSingHealthActive in the last 2 years

Brian K. P. Goh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8218-4576; OpenAlex author ID A5047305690. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 6 papers · 2026: 3 papers

Papers 12

  1. Pancreatic cancer burden across Southeast Asia from 1990 to 2021: An analysis of incidence and mortality based on the global burden of disease study 2021. Last author DOI 10.1016/j.pan.2025.09.031↗
  2. Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequent… Co-author DOI 10.1016/j.surg.2025.109872↗
  3. Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer. Co-author DOI 10.21037/tgh-2026-0026↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. SEER-based evaluation of lymph node yield as a prognostic indicator of cancer-specific survival in nonmetastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.05.008↗
  6. Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Contr… Co-author DOI 10.1245/s10434-024-16674-y↗
  7. ASO Author Reflections: Resectable Pancreatic Cancer Treatment to be Optimized with Accurate Biological Aggressiveness Staging and Risk Stratification in the F… First author DOI 10.1245/s10434-024-16812-6↗
  8. Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcomes, and cost-effectiveness. Co-author DOI 10.21037/gs-24-421↗
  9. Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant Therapy and Upfront Surgery with Propen… First author DOI 10.31557/apjcp.2025.26.3.847↗
  10. Resected pancreatic adenocarcinoma: An Asian institution's experience. Co-author DOI 10.1002/cnr2.1393↗
  11. Paraneoplastic Stiff Person Syndrome Secondary to Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11605-017-3611-y↗
  12. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal ade… Last author DOI 10.1245/s10434-014-3639-0↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ye Xin Koh · 10 shared papers, 2014–2026 · strength 2.83
  2. Hwee Leong Tan · 6 shared papers, 2025–2026 · strength 1.88
  3. Yun Zhao · 5 shared papers, 2025–2026 · strength 1.49
  4. Anna Ho Yin Chan · 2 shared papers, 2025 · strength 0.67
  5. Kennedy Yao Yi Ng · 3 shared papers, 2021–2026 · strength 0.65
  6. David Wai-Meng Tai · 3 shared papers, 2021–2026 · strength 0.65
  7. Yun Zhao · 1 shared paper, 2025 · strength 0.33
  8. Stephanie Yu Shan Yong · 1 shared paper, 2018 · strength 0.12
  9. Ser Yee Lee · 1 shared paper, 2021 · strength 0.10
  10. Pierce K. H. Chow · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.